Digital MSK company Hinge Health files for IPO: Investors might be intrigued by Hinge, even as digital health companies have been hesitant to go public in the past few years.
News and magazine apps have the highest engagement score in North America, with 29% of monthly active users coming back daily, according to a September 2024 Airship survey.
Everyone is talking about Hims’ Super Bowl weight loss drug ad: The reaction has been largely negative. We examine why it’s a gamble that will likely pay off for Hims.
Key stat: 19% of US adults play team sports, up from 11% in 2020, according to CivicScience, signaling that people aren’t only watching sports, they’re participating as well.
Study reveals Amazon Pharmacy’s RxPass improves medication adherence: Subscription programs for prescription drugs could be a model worth exploring for struggling retail pharmacy incumbents.
Patients like receiving educational health information in medical settings: We explore how advertising at points of care like the doctor’s office can trigger patient behavior while also delivering value to doctors.
How the FDA’s approval of non-opioid pain pill could benefit pharma players: Pharmacies and drugmakers hope that the new treatment will help them avoid opioid-related legal issues in the future.
Our take on RFK’s Senate hearing to date: His answers (or lack thereof) to pressing healthcare issues won’t do much to convince the American public he’s the right person to run the HHS.
Senators reintroduce Drug-price Transparency for Consumers Act: If passed, the Act could empower patients to make informed decisions about their healthcare amid a torrent of direct-to-consumer drug ads.
Caregivers in the US are overburdened: Healthcare and pharma companies have an opportunity to develop marketing strategies around providing them relief.
​​Hims blames drugmakers for high GLP-1 prices in Super Bowl TV spot: It’s a bold—and expensive—move for Hims, especially considering the uncertain future of compounded weight loss drugs and doctors’ growing apprehension of how these treatments are marketed and sold.
Consumers’ vaccine skepticism persists: Their growing distrust coupled with the spectre of RFK Jr. leading the HHS could portend bad news for Big Pharma
Neko Health secures $260M in Series B funding: The medical scanning startup is now valued at $1.8 billion, which feels overblown when you take consumers’ appetite for the service and ability to afford it into account.
On today’s podcast episode, we discuss the trend of healthcare and pharmaceutical brands selling prescription drugs, treatments, and medical services directly to consumers and how rising medical costs are changing patients’ relationship with the healthcare system. Tune in to the conversation with Senior Director of Podcasts and host Marcus Johnson, and Senior Analysts Dane Finley and Rajiv Leventhal. Listen everywhere and watch on YouTube and Spotify.
US hospitals use predictive AI tools, but many use biased data: Most AI models make recommendations based on homogenous data samples, which could actually harm many patients. But more regulatory oversight of healthcare AI isn’t guaranteed to happen in the near term.
Instagram, Facebook suppress content from abortion pill providers: The platforms are walking a tightrope between enforcing their community guidelines and alienating healthcare brands and patients.
Investments in women’s health startups are alarmingly low: Yet startups addressing conditions such as menopause have seen success when VC funding has gone their way, showing that investments in the space have a high potential for viable returns.
Gen Z struggles to manage health and wellness: They understand the importance of taking health into their own hands but fail to deliver good results. We explore how healthcare marketers, providers, and insurers can arm this generation with the necessary support.
Google DeepMind expects AI-designed drug trials to start this year: While the jury is out on how effective the tech is at accelerating drug discovery, that hasn’t stopped pharma companies from pursuing tie-ups with the firm to do just that.
Sanofi’s Opella secures FDA nod to pursue OTC Cialis study: If Cialis’ shift from a prescription drug to over-the-counter product comes to fruition, both consumers and D2C retailers could benefit.